Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Lexaria Bioscience Corp. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 318.1K | 417.4K | +99.3K (+31.2%) |
| Value | $1.78M | $2.93M | +$1.14M (+63.9%) |
New holders (4)
Institutions that held Lexaria Bioscience Corp. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 50,385 | $352.0K | 0.00% |
| Vanguard Group Inc | 25,976 | $182.0K | 0.00% |
| Renaissance Technologies LLC | 17,200 | $120.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 251 | $2.00K | 0.00% |
Sold out (3)
Institutions that held Lexaria Bioscience Corp. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Citadel Advisors LLC | 14,915 | $84.0K |
| Bank of America Corp | 145 | $1.00K |
| Bank of Montreal | 33 | $0 |